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A B S T R A C T
Background
Antiretroviral drugs have been shown to reduce risk of mother-to-child transmission of human immunodeficiency virus (HIV) and
are also widely used for post-exposure prophylaxis for parenteral and sexual exposures. Sexual transmission may be lower in couples in
which one partner is infected with HIV and the other is not and the infected partner is on antiretroviral therapy (ART).
Objectives
To determine if ART use in an HIV-infected member of an HIV-discordant couple is associated with lower risk of HIV transmission
to the uninfected partner compared to untreated discordant couples.
Search methods
We used standard Cochrane methods to search electronic databases and conference proceedings with relevant search terms without
limits to language.
Selection criteria
Randomised controlled trials (RCT), cohort studies and case-control studies of HIV-discordant couples in which the HIV-infected
member of the couple was being treated or not treated with ART
Data collection and analysis
Abstracts of all trials identified by electronic or bibliographic scanning were examined independently by two authors. We initially
identified 3,833 references and examined 87 in detail for study eligibility. Data were abstracted independently using a standardised
abstraction form.
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Main results
One RCT and nine observational studies were included in the review. These ten studies identified 2,112 episodes of HIV transmission,
1,016 among treated couples and 1,096 among untreated couples. The rate ratio for the single randomised controlled trial was 0.04
[95% CI 0.00, 0.27]. All index partners in this study had CD4 cell counts at baseline of 350-550 cells/µL. Similarly, the summary rate
ratio for the nine observational studies was 0.58 [95% CI 0.35, 0.96], with substantial heterogeneity (I2=64%). After excluding two
studies with inadequate person-time data, we estimated a summary rate ratio of 0.36 [95%CI 0.17, 0.75] with substantial heterogeneity
(I2=62%). We also performed subgroup analyses among the observational studies to see if the effect of ART on prevention of HIV
differed by the index partner’s CD4 cell count. Among couples in which the infected partner had ≥350 CD4 cells/µL, we estimated a
rate ratio of 0.12 [95% CI 0.01, 1.99]. In this subgroup, there were 247 transmissions in untreated couples and 30 in treated couples.
Authors’ conclusions
ART is a potent intervention for prevention of HIV in discordant couples in which the index partner has≤550 CD4 cells/µL. A recent
multicentre RCT confirms the suspected benefit seen in earlier observational studies and reported in more recent ones. Questions
remain about durability of protection, the balance of benefits and adverse events associated with earlier therapy, long-term adherence
and transmission of ART-resistant strains to partners. Resource limitations and implementation challenges must also be addressed.
Counselling, support, and follow up, as well as mutual disclosure, may have a role in supporting adherence, so programmes should
be designed with these components. In addition to ART provision, the operational aspects of delivering such programmes must be
considered.
P L A I N L A N G U A G E S U M M A R Y
Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples
Antiretroviral drugs can prevent transmission of HIV from an infected sexual partner to an uninfected one, by suppressing viral
replication. We found one randomised controlled trial and nine observational studies that examined this question. Overall we found
that in couples in which the infected partner was being treated with antiretroviral drugs the uninfected partners had, at worst, more
than 40% lower risk of being infected than in couples where the infected partner was not receiving treatment. Since the World Health
Organization (WHO) already recommends antiretroviral treatment for all persons with ≤350 CD4 cells/µL, we also examined studies
that had studied couples in which the infected partners had CD4 counts higher than this level. We found that there is strong evidence
from the randomised controlled trial that in this groupHIV was less likely to be transmitted to uninfected partners from treated infected
partners than from untreated infected partners.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Antiretroviral Therapy for HIV Prevention in Serodiscordant Couples (Part A)
Patient or population: Serodiscordant couples
Settings: Botswana, Brazil, China, India, Italy Malawi, Kenya, Rwanda, South Africa, Spain, Thailand, Uganda, United States of America, Zambia and Zimbabwe
Intervention: Antiretroviral Therapy
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Antiretroviral therapy
Virologically linked HIV
incidence (RCT)
17 per 10005,8 1 per 1000
(0 to 5)5,8
Rate Ratio 0.04
(0.00 to 0.27)
1750
(1 study)
⊕⊕⊕⊕
high5,8
HIV incidence (observa-
tional studies)
54 per 10001,2 31 per 1000
(19 to 51)1,2
Rate Ratio 0.58
(0.35 to 0.96)
46204
(9 studies)
⊕⊕⊕©
moderate3
HIV incidence (observa-
tional studies--sensitiv-
ity analysis)
48 per 10001,2 17 per 1000
(8 to 36)1,2
Rate Ratio 0.36
(0.17 to 0.75)
46560
(7 studies)
⊕⊕⊕©
moderate4,5
HIV incidence: CD4 sub-
groups (<200 cells/µL)
(observational studies)
48 per 10002,6 6 per 1000
(1 to 39)2,6
RR 0.12
(0.02 to 0.81)
26594
(5 studies)
⊕⊕©©
low5,7,8
HIV incidence: CD4 sub-
groups (200-350 CD4
cells/µL) (observational
studies)
28 per 10002,6 18 per 1000
(13 to 26)2,6
RR 0.66
(0.47 to 0.92)
9595
(4 studies)
⊕©©©
very low3,8,9
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HIV incidence: CD4 sub-
groups (350 or more
CD4 cells/µL) (observa-
tional studies)
25 per 10002,6 3 per 1000
(0 to 49)2,6
RR 0.12
(0.01 to 1.99.)
13426
(3 studies)
⊕⊕©©
low5,8,10
Virologically linked HIV
incidence: CD4 sub-
groups (350 or more
CD4 cells/µL) (RCT)
17 per 10005,8 1 per 1000
(0 to 5)5,8
RR 0.04
(0.00 to 0.27)
1750
(1 study)
⊕⊕⊕⊕
high5,8
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
RCT: randomised controlled trial; CI: confidence interval; RR: risk ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Less than 5% of sample was imputed due to missing information in the denominator.
2 Numerators and Denominators taken from text where possible. Numbers were not used to calculate the relative effect estimates.
3 Rate Ratio ~0.50
4 Two studies were removed due to differences in intervention or incomplete data.
5 RR <0.35
6 Due to missing information in the denominator and/or numerator, some data were imputed from text.
7 No person time available for 3 out of 5 studies.
8 Few events and/or wide confidence interval.
9 No person time available for 2 out of 4 studies.
10 No person time available for 1 out of 3 studies.
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B A C K G R O U N D
Antiretroviral drugs have been shown to reduce risk of mother-
to-child transmission of human immunodeficiency virus (HIV)
(Siegfried 2011), and are widely used for post-exposure prophy-
laxis for parenteral and sexual exposures (Young 2007, Grant
2010), although these indications have not been examined in ran-
domised controlled trials (RCT) (Young 2007). They are also effi-
cacious in preventing acquisition of HIV infection by uninfected
individuals (pre-exposure prophylaxis) (Okwundu 2012). Sexual
transmission is lower in couples in which one partner is infected
with HIV and the other is not and the infected partner is on an-
tiretroviral therapy (ART) (Anglemyer 2011b), and models indi-
cate widespread prevention benefit if large numbers of infected
patients in a population are treated (Granich 2009). Ecological
studies fromTaiwan (Fang 2004), British Columbia (Wood 2009,
Gill 2010, Montaner 2010) and San Francisco (Porco 2004, Das
2010) have found that transmission has decreased as the propor-
tion of treated patients increases and community viral load de-
creases (Das 2010).
In a cohort analysis of couples followed in a trial of sexually trans-
mitted disease control for prevention ofHIV in the era before ART
was widely available in rural Africa, risk of sexual transmission in
discordant couples was lowest in couples in which the infected
partner had an HIV serum viral load of <400 copies/mL (Quinn
2000). Similarly, data from trials and cohort studies of mother-to-
child transmission of HIV have demonstrated that mothers with
the lowest viral loads are the least likely to transmit (Jourdain
2007). While plasma (or serum in the case of Quinn 2000) vi-
ral loads do not necessarily directly correlate with viral loads in
semen or cervico-vaginal secretions and HIV can continue to be
shed despite non-detectable plasma viral loads (Sheth 2009), the
absence of detectable HIV RNA in plasma roughly corresponds to
lower levels of HIV RNA in genital tract secretions (Vettore 2006,
Lorella 2009). Moreover, a recently published simulation model
aimed to estimate the risk of HIV transmission, in the context
of condom use, from homosexual men treated with ART to their
partners (Hallett 2011) and found that, even when never using
condoms with long-term partners, the predicted risk of transmis-
sion to long-term partners was only 22%.
Taken together this body of literature suggests that treating an in-
fected individual with ART may decrease the risk of sexual trans-
mission to his or her uninfected partners. In this review we exam-
ine whether treating an HIV-infected partner (or “index” partner)
with ART is associated with decreased risk of acquiring HIV in an
uninfected member of a discordant couple.
Description of the condition
HIV infection is a chronic retroviral infection of humans that is
almost universally fatal if left untreated. HIV can be transmitted
sexually, parenterally or perinatally; globally sexual transmission
accounted for about 70% of the 2.7 million new HIV infections
in 2008 (UNAIDS 2009). Data from Africa suggest that more
than half of new infections are occurring in stable couples who are
serodiscordant for HIV infection, meaning that one member of
the couple is infected and the other is not (Dunkle 2008, Mermin
2008).
Description of the intervention
Use of any antiretroviral drugs alone or in combination in HIV-
infected members of discordant couples.
Inclusion criteria:
• Randomised controlled trial (RCT), cohort study or case-
control study
• Compares HIV-discordant couples in which the HIV-
infected member is treated or not treated
• Provides sufficient regimen-specific information about
drugs to compare regimens and outcomes of interest
Exclusion criteria:
• Studies in which all HIV-infected members of discordant
couples are either all treated or all not treated
• Letter, editorial, non-systematic review, case report, case
series, cross-sectional study
How the intervention might work
By suppressing HIV replication systemically and decreasing HIV
shedding in the genital tract.
Why it is important to do this review
If there is, indeed, prevention benefit from ART, in addition to its
well-established therapeutic efficacy, the weight of evidence may
shift to treating infected patients earlier in the course of their
infection than is currently recommended (WHO 2010).
O B J E C T I V E S
To assess if ART is associated with decreased risk of HIV transmis-
sion from an infected sexual partner to an uninfected sexual part-
ner. Additionally, this review aims to assess specifically if ART in a
patient with ≥350 CD4 cells/µL is also associated with a lowered
risk of HIV transmission.
M E T H O D S
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Criteria for considering studies for this review
Types of studies
RCTs, cohort studies and case-control studies that included data
and analysis for the comparison of interest.
Types of participants
HIV-discordant couples that is, stable sexual partnerships inwhich
one member is infected with HIV and the other uninfected. Stud-
ies with heterosexual or homosexual couples were eligible for in-
clusion.
Types of interventions
Use of any antiretroviral drugs alone or in combination in HIV-
infected members of discordant couples. Variations of interest in-
cluded patients receiving HIV monotherapy, those receiving dual
therapy and those receiving the current standard of three or more
antiretroviral drugs (Jourdain 2007).
Types of outcome measures
Primary outcomes
• Incident HIV Infection
• Incident HIV Infection with viral isolates matched from
index patient to newly infected partner
Secondary outcomes
• Acquisition of primary drug-resistant HIV. This is defined
as an incident infection with an HIV strain resistant to one or
more standard antiretroviral drugs.
• Severe adverse events in participants receiving treatment
(Grade IV and life-threatening)
Search methods for identification of studies
See searchmethods used in reviews by the Cochrane Collaborative
Review Group on HIV Infection and AIDS.
Electronic searches
We formulated a comprehensive and exhaustive search strategy in
an attempt to identify all relevant studies regardless of language
or publication status (published, unpublished, in press and in
progress). Full details of the Cochrane HIV/AIDS Review Group
methods and the journals hand-searched are published in the sec-
tion on Collaborative Review Groups in The Cochrane Library.
Journal and trials databases
We searched the following electronic databases, in the period from
01 January 1987 to 31 August 2012:
• PubMed
• EMBASE
• Cochrane Central Register of Controlled Trials
(CENTRAL)
• Web of Science
• LILACS
Along with MeSH terms and relevant keywords, we used the
Cochrane Highly Sensitive Search Strategy for identifying reports
of RCTs in MEDLINE (Higgins 2008), and the Cochrane HIV/
AIDSGroup’s existing strategies for identifying references relevant
to HIV/AIDS. The search strategy was iterative, in that references
of included studies were searched for additional references. All lan-
guages were included. See Appendix 1 for example of our PubMed
search strategy, which was modified as appropriate for use in the
other databases. In searching conference abstract archives, it was
not possible to perform complex searches. Instead, we used a va-
riety of relevant terms, individually and in simple combinations.
See Appendix 2 for these terms, and the yields from these searches.
Using a variety of relevant terms, we also searched the clinical trials
registry at the USNational Institutes of Health’s ClinicalTrials.gov
(www.clinicaltrials.gov).
Limits. The searches were performed without limits to language
or setting and limited to human studies published from1987 (start
of the antiretroviral era) to the present.
Searching other resources
Conference abstract databases
Using a variety of relevant terms, we searched the Aegis archive of
HIV/AIDS conference abstracts (www.aegis.org), which includes
the following conferences:
• British HIV/AIDS Association, 2001-2008
• Conference on Retroviruses and Opportunistic Infections
(CROI), 1994-2008
• European AIDS Society Conference, 2001 and 2003
• International AIDS Society, Conference on HIV
Pathogenesis, Treatment and Prevention (IAS), 2001-2005
• International AIDS Society, International AIDS
Conference (IAC), 1985-2004
• US National HIV Prevention Conference, 1999, 2003, and
2005
We also searched the CROI and International AIDS Society web
sites for abstracts presented at conferences subsequent to those
listed above (CROI, 2009-2012; IAC, 2006-2012; IAS, 2007-
2011).
Researchers and relevant organizations. We contacted individ-
ual researchers working in the field, such as the AIDS Clinical Tri-
als Group, and policymakers based in inter-governmental organi-
6Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
zations including the Joint United Nations Programme on HIV/
AIDS (UNAIDS) and WHO to identify studies either completed
or ongoing.
Reference lists.We checked the reference lists of all studies iden-
tified by the above methods and examined the bibliographies of
any systematic reviews, meta-analyses, or current guidelines we
identified during the search process.
Data collection and analysis
The methodology for data collection and analysis was based on
the guidance of Cochrane Handbook of Systematic Reviews of
Interventions (Higgins 2008). Abstracts of all trials identified by
electronic or bibliographic scanning were examined by two au-
thors (AA and GWR) working independently. Where necessary,
the full text was obtained to determine the eligibility of studies for
inclusion.
Selection of studies
After removing duplicate references, One author (TH) made the
first broad cut of these results, excluding those that were clearly
irrelevant (e.g. animal studies, editorials, paediatric studies, studies
without HIV endpoints).
Two authors (AA and GWR) then independently selected poten-
tially relevant studies by scanning the titles, abstracts, and descrip-
tor terms of the remaining references and applied the inclusion
criteria. Irrelevant reports were discarded, and the full article or
abstract was obtained for all potentially relevant or uncertain re-
ports. The two authors independently applied the inclusion cri-
teria. Studies were reviewed for relevance, based on study design,
types of participants, exposures and outcomes measures. A neu-
tral third party was available to adjudicate any disagreements that
could not have been resolved by discussion.
Data extraction and management
After initial search and article screening, two reviewers indepen-
dently double-coded and entered information from each selected
study onto standardised data extraction forms. Extracted informa-
tion included:
• Study details: citation, start and end dates, location, study
design and details.
• Participant details: study population eligibility (inclusion
and exclusion) criteria, ages, population size, attrition rate,
details of HIV diagnosis and disease and any clinical,
immunologic or virologic staging or laboratory information on
the infected partner.
• Interventions details: Drug names, doses, duration and
any other information on adherence or resistance.
• Outcome details: Incident HIV infection in the uninfected
partner, acquisition of a drug-resistant strain of HIV
Assessment of risk of bias in included studies
We used the Cochrane Collaboration tool for assessing the risk of
bias for each individual study and present results in a summary
table (Figure 1). For trials, theCochrane tool assesses risk of bias in
individual studies across six domains: sequence generation, allo-
cation concealment, blinding, incomplete outcome data, selective
outcome reporting and other potential biases.
Figure 1. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Sequence generation
• Adequate: investigators described a random component in
the sequence generation process, such as the use of random
number table, coin tossing, card or envelope shuffling, etc.
• Inadequate: investigators described a non-random
component in the sequence generation process, such as the use of
odd or even date of birth, algorithm based on the day or date of
birth, hospital, or clinic record number.
• Unclear: insufficient information to permit judgement of
the sequence generation process.
Allocation concealment
• Adequate: participants and the investigators enrolling
participants cannot foresee assignment (e.g., central allocation;
or sequentially numbered, opaque, sealed envelopes).
• Inadequate: participants and investigators enrolling
participants can foresee upcoming assignment (e.g., an open
random allocation schedule, a list of random numbers); or
envelopes were unsealed or non-opaque or not sequentially
numbered.
• Unclear: insufficient information to permit judgement of
the allocation concealment or the method not described.
Blinding
• Adequate: blinding of the participants, key study personnel,
and outcome assessor, and unlikely that the blinding could have
been broken. No blinding in the situation where non-blinding is
not likely to introduce bias.
• Inadequate: no blinding or incomplete blinding when the
outcome is likely to be influenced by lack of blinding.
• Unclear: insufficient information to permit judgement of
adequacy or otherwise of the blinding.
Incomplete outcome data
• Adequate: no missing outcome data, reasons for missing
outcome data unlikely to be related to true outcome, or missing
outcome data balanced in number across groups.
• Inadequate: reason for missing outcome data likely to be
related to true outcome, with either imbalance in number across
groups or reasons for missing data.
• Unclear: insufficient reporting of attrition or exclusions.
Selective reporting
• Adequate: a protocol is available which clearly states the
primary outcome as the same as in the final trial report.
• Inadequate: the primary outcome differs between the
protocol and final trial report.
• Unclear: no trial protocol is available or there is insufficient
reporting to determine if selective reporting is present.
Other forms of bias
• Adequate: there is no evidence of bias from other sources.
• Inadequate: there is potential bias present from other
sources (e.g., early stopping of trial, fraudulent activity, extreme
baseline imbalance, or bias related to specific study design).
• Unclear: insufficient information to permit judgement of
adequacy or otherwise of other forms of bias.
We used theNewcastle-Ottawa Scale (Newcastle-Ottawa) to assess
the quality and risk of bias in non-randomised studies. Specifically,
the scale uses a star system to judge three general areas: selection
of study groups, comparability of groups, and ascertainment of
outcomes (in the case of cohort studies). As a result, this instrument
can assess the quality of non-randomised studies so that they can
be used in a meta-analysis or systematic review. Please see Figure
2 and Appendix 3 for details.
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Figure 2. Newcastle-Ottawa Scale for Bias Assessment
Assessment of Quality of Evidence Across Studies
We assessed the quality of evidence across a body of evidence (i.e.,
multiple studies with similar interventions and outcomes) with the
GRADE approach (Guyatt 2008), defining the quality of evidence
for each outcome as “the extent to which one can be confident that
an estimate of effect or association is close to the quantity of specific
interest” (Higgins 2008). The quality rating across studies has
four levels: high, moderate, low or very low. RCTs are categorised
as high quality but can be downgraded; similarly, other types of
controlled trials and observational studies are categorised as low
quality but can be upgraded. Factors that decrease the quality of
evidence include limitations in design, indirectness of evidence,
unexplained heterogeneity or inconsistency of results, imprecision
of results or high probability of publication bias. Factors that can
increase the quality level of a body of evidence include a large
magnitude of effect, if all plausible confounding would lead to an
underestimation of effect and if there is a dose-response gradient.
See Summary of findings for the main comparison and Summary
of findings 2.
Measures of treatment effect
We used Review Manager 5 provided by the Cochrane Collabora-
tion for statistical analysis and GRADEpro software (GRADEpro
2008) to produce GRADE Summary of Findings tables and
GRADE evidence profiles. We summarised dichotomous out-
comes for effect in terms of risk ratio (RR), rate ratio and number
needed to treat (NNT) with their 95% confidence intervals. Tests
for interaction (i.e. Ratio of Risk Ratios, RRR) were performed to
compare estimates within subgroups using methods described in
Altman et al (Altman 2003).
We summarised rate data in terms of rate ratios with their 95%
confidence intervals. Standard errors for each estimate were es-
timated using methods described in Rothman et al (Rothman
1998).
We calculated summary statistics usingmeta-analyticmethods and
present findings in GRADE Summary of Findings tables for all
outcomes of interest.
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Unit of analysis issues
The unit of analysis was the individual partner in the discordant
couple who was uninfected at baseline in each study.
Dealing with missing data
Study authors were contacted when missing data were an issue.
Assessment of heterogeneity
We examined heterogeneity among the observational studies us-
ing the χ2 statistic with a significance level of 0.10, and the I2
statistic. We interpreted an I2 estimate greater than 50% as indi-
cating moderate or high levels of heterogeneity and investigated
its causes by sensitivity analysis. If heterogeneity persisted, we re-
ported potential reasons for the observed heterogeneity.
Assessment of reporting biases
We assessed the potential for publication bias for the trial and
for the observational studies using funnel plots. We attempted to
minimise the potential for publication bias by our comprehen-
sive search strategy that included evaluating published and unpub-
lished literature.
Data synthesis
When interventions and study populations were sufficiently sim-
ilar across the different observational studies, we pooled the data
across studies and estimated summary effect sizes using both fixed-
and random-effects models. Specifically, we estimated the log(rate
ratio) for each included study andused the inverse variancemethod
to calculate study weights. The inverse variance method assumes
that the variance for each study is inversely proportional to its
importance, therefore more weight is given to studies with less
variance than studies with greater variance.
We summarised the quality of evidence for the trial and the obser-
vational studies separately for each outcome for which data were
available in GRADE Summary of Findings tables and GRADE
evidence profiles (Guyatt 2008).
Subgroup analysis and investigation of heterogeneity
We performed sub-group analysis in the observational studies by
baselineCD4counts in index partners andby gender of index part-
ners. Heterogeneity was explored using further sub-group analyses
by setting (middle- or low- versus high-income country). A test
for interaction was performed for each subgroup comparison.
Sensitivity analysis
As pooled results were heterogeneous for the observational studies,
we conducted sensitivity analyses to identify studies with outlying
results for further examination.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
Searches for the first version of this review (Anglemyer 2011a) were
conducted on February 1, 2011. The review was updated three
months later (Anglemyer 2011b) after the data and safety mon-
itoring board of a trial in progress (Cohen 2011) recommended
that its findings be released ahead of schedule. Those findings
were included in the review’s second version (Anglemyer 2011b).
Searches for the review’s current version were conducted on Au-
gust 31, 2012.
The searches on February 1, 2011 produced 1,483 titles after 331
duplicates were removed. After initial screening of titles by one au-
thor (TH), 237 titles and abstracts were selected for further review
by two authors (AA and GWR). AA and GWR independently
conducted the selection of potentially relevant studies by scanning
the titles, abstracts, and descriptor terms of all downloaded mate-
rial from the electronic searches. Irrelevant reports were discarded,
and the full article was obtained for all potentially relevant or un-
certain reports. AA and GWR independently applied the inclu-
sion criteria. NS acted as arbiter where there was disagreement.
Studies were reviewed for relevance, based on study design, types
of participants, exposures and outcomes measures. Finally, where
resolution was not possible because further information was re-
quired, the study was allocated to the list of those awaiting as-
sessment. Twenty-three full-text articles were closely examined by
two authors (AA and GWR). In the review’s initial publication
(Anglemyer 2011a), seven observational studies were included.
The second version (Anglemyer 2011b) added RCT data from
Cohen 2011. It thus included one RCT and seven observational
studies. See Figure 3 for a flowchart of the screening process for
Anglemyer 2011b.
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Figure 3. Screening process, PREVIOUS version of the review (Anglemyer 2011b)
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The searches on August 31, 2012 produced 2,350 titles after 720
duplicates were removed. After initial screening of titles by one au-
thor (TH), 882 titles and abstracts were selected for further review
by two authors (AA and GWR). AA and GWR independently
conducted the selection of potentially relevant studies by scanning
the titles, abstracts, and descriptor terms of all downloaded mate-
rial from the electronic searches. Irrelevant reports were discarded,
and the full article was obtained for all potentially relevant or un-
certain reports. AA and GWR independently applied the inclu-
sion criteria. TH acted as arbiter where there was disagreement.
Studies were reviewed for relevance, based on study design, types
of participants, exposures and outcomes measures. Finally, where
resolution was not possible because further information was re-
quired, the study was allocated to the list of those awaiting assess-
ment. Sixty-four full-text articles were closely examined by two
authors (AA and GWR). Two new cohort studies were identified.
In the current review, one RCT and nine cohort studies met our
inclusion criteria for data extraction, coding and potential meta-
analysis. See Figure 4 for a flowchart of the screening process for
the current review.
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Figure 4. Screening process, CURRENT version of the review.
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Included studies
The RCT was conducted in nine countries: Botswana, Brazil,
India, Malawi, Kenya, South Africa, Thailand, United States of
America and Zimbabwe (Cohen 2011). This trial mostly included
heterosexual partners, but 3% homosexual partners were also
included. The nine included cohort studies were conducted in
Italy (Musicco 1994), Brazil (Melo 2008), Zambia and Rwanda
(Sullivan 2009), Uganda (Reynolds 2011, Birungi 2012), Spain
(Del Romero 2010), China (Lu 2010, Jia 2012) and Botswana,
Kenya, Rwanda, South Africa, Tanzania, Uganda, and Zambia
(Donnell 2010). Two studies appeared both in abstract and print
form (Del Romero 2010, Donnell 2010). Six of the nine observa-
tional studies were of partners of persons infected heterosexually
(Musicco 1994, Sullivan 2009, Donnell 2010, Lu 2010, Reynolds
2011, Birungi 2012), one was of partners in either heterosexual
or same-sex relationships (Jia 2012), and two were predominantly
of heterosexual partners of injection drug users (Melo 2008, Del
Romero 2010). In eight observational studies (Melo 2008, Sullivan
2009,Del Romero 2010,Donnell 2010, Lu2010, Reynolds 2011,
Birungi 2012, Jia 2012) infected partners received three or more
antiretroviral drugs, and in one early study they received zidovu-
dine (AZT) monotherapy only (Musicco 1994).
Musicco 1994: Musicco and colleagues conducted a cohort study
in Italy, which was published in 1994 in the era before the advent
of combination ART. They followed a cohort of 436monogamous
HIV-uninfected female sexual partners of HIV-infected men re-
cruited from 16 centres in Italy. Seventy-nine percent of the male
index patients had histories of injection drug use, 25% had symp-
toms of AIDS, and 48% had fewer than 400 CD4 cells/µL. There
were 27 seroconversions observed, 21 in partners of men whowere
not receiving AZT monotherapy and 6 in partners of men who
were. Incidence in the untreated group was 4.4 per 100 person
years (95% confidence interval [CI] 2.6-5.7) and 3.8 (95% CI
1.4-8.3) in the treated group (unadjusted rate ratio 0.88, 95% CI
0.36-2.16). However, when adjusted for consistent condom use,
presence of p24 antigen, CD4 counts and symptoms of AIDS in
infected male partners, the relative risk of female partners of men
treated with AZT acquiring HIV was 50% lower (RR 0.5, 95%
CI 0.1-0.9) when compared to female partners of men not treated
with AZT.
Melo 2008: Melo and colleagues followed a cohort of 93 discor-
dant couples in Porto Alegre, Brazil, in which the female member
of the couple was infected in 67 (72%) and the male in 26 (28%).
Fifteen (58%) of the 26 male and 6 (9%) of the female index cases
had histories of injection drug use. Of the 26 male index cases,
5 (19%) had CD4 counts <350 cells/µL; of the 67 female index
cases, 3 (5%) had <350 CD4 cells/µL, and 33 (49%) were preg-
nant at baseline. Comparing treated to untreated serodiscordant
couples, their results suggest a protective effect of ART (rate ratio=
0.10; 95% CI 0.01-1.67).
Sullivan 2009: Sullivan and colleagues presented data from two
cohorts of 2,993 HIV-discordant couples in Rwanda and Zambia
followed from 2002 to 2008. No additional background data on
cohort members were available from the conference abstract. They
observed 175 new infections of which 4 were from partners of
index cases on ART. Incidence density was 3.4% per 100 person-
years for those whose partners were not taking ART and 0.7%
for those whose partners were taking ART (rate ratio= 0.21, 95%
CI 0.08-0.59). An earlier abstract also reported on this cohort
(Kayitenkore 2006).
Del Romero 2010: Del Romero and colleagues analysed data from
648heterosexual couples attending a clinic inMadrid, Spain, from
1989 to 2008, where uninfected partners were examined for preva-
lent HIV infection. Five hundred thirty-five (83%) of the index
cases were male and 113 (17%) female. Of the 648 index cases,
494 (76%) had histories of injection drug use.Median CD4 count
was 500 cells/µL. Clinical AIDS had been diagnosed at baseline
in 107 (17%) of index cases. Forty-six partners were found to
have prevalent HIV infection when examined prior to follow-up.
Forty-four of these occurred in partners of index cases who had
received no ART, and 2 were in partners of index cases who had re-
ceived either monotherapy or dual therapy. Four hundred twenty-
four serodiscordant couples had follow-up information collected
over 1355 couple years. Five transmission events occurred in un-
treated couples over 863 couple years, and no transmissions oc-
curred among treated couples over 492 couple years (rate ratio
0.21; 95% CI 0.01-3.75). Earlier studies also analysed this cohort
(Castilla 2005).
Donnell 2010: Donnell and colleagues reported data in an ab-
stract from a prospective cohort analysis of an RCT of hetero-
sexual African adults who were seropositive for both HIV and
herpes simplex virus type 2 (HSV-2) and their HIV-uninfected
sexual partners. Three thousand four hundred eight couples were
enrolled from seven countries (Botswana, Kenya, Rwanda, South
Africa, Tanzania, Uganda and Zambia). Of the 3,381 infected in-
dex cases, 2,284 (68%) were female and 1,097 (32%) were male.
The median CD4 count of index patients was 462 cells/µL, the
median plasma viral load was 4.1 log10 copies/mL, and 34% of
infected male partners and 55% of uninfected male partners were
circumcised. One hundred three genetically linked new infections
were identified in partners; one was in the partner of a treated
index case. The incidence in partners of untreated index cases was
2.24 (1.84-2.72) per 100 person-years as compared to 0.37 (95%
CI 0.09-2.04) per 100 person-years in partners of treated index
cases (adjusted incidence rate ratio 0.08, 95%CI 0.00-0.57). This
population was previously analysed in another abstract (Donnell
2009).
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Lu 2010: Lu and colleagues analysed data from a prospective co-
hort study that enrolled 1927 heterosexual couples between Jan-
uary 2006 andDecember 2008 for testing and treatment at county
hospitals inChina. Serodiscordant coupleswere identified through
an HIV database and enrolled at local hospitals and health cen-
tres. The couples received HIV testing every 6 months and in the
event of transmission to an uninfected partner, a recent history of
sexual behaviours was taken from the participants. Of the 1927
couples, there were 1092 (57%) HIV-infected male partners and
835 (43%) HIV-infected female partners. The last recorded CD4
count was <200 cells/µL for 422 index spouses (23%), and ≥350
cells/µ for 675 (35%) index partners. Approximately 80% of the
studied couples were treated with antiretroviral therapy. Eighty-
four (4%) partners seroconverted by the end of follow up, yielding
an overall rate of 1.71 per 100 person-years. There was no relation-
ship between the rate of seroconversion and last CD4 count in the
index spouse. There was also no effect of ART on preventing HIV
transmission in this study as 4.8% of treated couples and 3.2% of
untreated couples seroconverted (yielding a non-significant rate
ratio of 1.44; 95% CI 0.85-2.44).
Cohen 2011: This was a Phase III, two-arm,multicentre RCT that
enrolled 1750 serodiscordant heterosexual and male homosexual
couples. All index cases had 350-550 CD4 cells/µL at baseline and
were randomly assigned to immediate ART treatment initiation
or delayed treatment until two consecutive measurements of 200-
250 CD4 cells/µL or an AIDS defining illness (HPTN 2011). No
participants had histories of injection drug use. All serodiscordant
couples were given prevention and adherence counseling and pro-
vided with free condoms. In the immediate treatment arm over
1585 person years, there was one HIV transmission to partner that
was linked by virological genomic analysis to that of the index case.
In the delayed treatment arm over 1567 person years, there were
27 linked HIV transmissions, yielding a rate ratio of 0.04 (95%
CI 0.00-0.27). When considering all HIV infections, regardless
of confirmatory linkages, there were 35 HIV transmissions in the
delayed arm and 4 transmissions in the immediate arm (rate ratio
0.11; 95%CI 0.04-0.32). Subsequent analyses identified 38 cases,
from which 29 (76.3%) were definitively linked using a phyloge-
netic analysis of HIV pol sequences, and in 7 cases (18.4%) the
index partner was ruled out as a likely source of HIV infection
(Eshleman 2011).
Reynolds 2011: Reynolds and colleagues reported data from a
cohort of 250 HIV-discordant couples from Rakai, Uganda. They
observed 42 seroconversions over 459 person-years of exposure to
index patients not on ART (incidence 9.2 per 100 person-years,
95% CI 6.6-12.4) and none over 53.6 person-years on ART (rate
ratio= 0.10; 95% CI 0.01-1.64).
Birungi 2012: Birungi and colleagues examined the effectiveness
of ART as prevention in a programmatic setting in rural Uganda
without access to viral load testing. The authors enrolled 550
serodiscordant couples and began HAART in 260 couples (CD4
<=250 or WHO stage IV illness) and delayed treatment in 290
couples not yet eligible for ART. All couples were tested every 3
months. Ultimately, 586 couples were enrolled with 348 couples
(59%) of the positive participants received ART during the study
(249 on ART at enrolment; 99 began ART after enrolment). Me-
dian ART-use at enrolment was 2.5 years among couples treated
with ART. Median follow up was 1.3 years for all couples. There
were 17 infections diagnosed during the follow-up (9 infections
in the ART group and 8 infections in the non-ART group). In-
cidence was estimated as 2.09 infections per 100 person years for
the ART group and 2.30 infections per 100 person years for the
non-ART group. The overall incidence rate ratio was 0.91 (95%
CI 0.38-2.20).
Jia 2012: This was a large, national-level study assessing the ef-
fect of antiretroviral therapy onHIV transmission risk among dis-
cordant couples across China from January 2003 to December
2011. All HIV-infected individuals in China who reported having
a spouse or regular sex partnerwere followedby theChineseCentre
forDiseaseControl andPrevention (ChinaCDC). Every 6months
HIV-negative partners were tested and HIV-infected partners re-
ceived repeat CD4 cell count tests. A total of 24,057 discordant
couples were identified for the ART-treated cohort and 14,805
discordant couples were identified for the ART-naive cohort and
followed over 101,295.1 person-years. Over all couples, a total of
1631 HIV transmissions occurred for an overall rate of 1.6 trans-
mission per 100 person-years (95% CI 1.5-1.7). Among treated
couples, the rate was 1.3 per 100 person years (95% CI 1.2-1.3)
and among the untreated couples the transmission rate was 2.6 per
100 person years (95% CI 2.4-2.8), yielding an unadjusted HR=
0.61 (95% CI 0.55-0.67). After adjusting for duration of follow-
up, sociodemographic variables, route of HIV infection, and base-
line CD4 among index cases, the authors estimated a HR=0.74
(95% CI 0.65-0.84). Considering couples treated with baseline
CD4 < 250 compared to couples untreated the unadjusted HR=
0.57 (95% CI 0.45-0.72). Similarly, considering couples treated
with baseline CD4 250-349 compared to couples untreated the
unadjustedHR=0.66 (95%CI 0.47-0.94). Lastly, comparing cou-
ples treated with baseline CD4 350 or greater with untreated cou-
ples, HR=0.45 (95% CI 0.31-0.66).
Excluded studies
We excluded data from 13 couples transmission studies in which
ART was not given (Operskalski 1997, Ragni 1998, Quinn 2000,
Fideli 2001,Gray2001,Tovanabutra 2002 ,Brill 2003,Mehendale
2004, Wawer 2005, Kayitenkore 2006, Peterson 2007, Peters
2008, Baeten 2010) and3 couples transmission studies inwhich all
index cases received ART (Barreiro 2006, Bunnell 2006, Bunnell
2008). See Excluded studies for details.
Risk of bias in included studies
In addition to Cochrane Collaboration’s tool for assessing the risk
of bias for each individual study (Higgins 2008), we applied the
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Newcastle-Ottawa Scale for bias assessment within observational
studies to all included observational studies (Newcastle-Ottawa).
The risk of bias for the included observational studies was as-
sessed on the data andoutcomes publishedwithin themanuscripts.
Please see Figure 2 and Appendix 3 for assessment results from the
Newcastle-Ottawa Scale and Cochrane risk of bias assessments.
All observational studies had cohorts that were representative of
treated and untreated, serodiscordant couples. Only three out of
the nine included observational studies that estimated the effect of
ART after adjusting for either age, sex, or frequency of sex among
serodiscordant couples. Three of nine observational studies explic-
itly described complete follow up of the study participants and/or
described the characteristics of the participants lost to follow up.
Allocation
In the trial randomisation was stratified by site using permuted
block randomisation to achieve approximately 1:1 allocation to
each treatment group within each site.
Blinding
The trial was unblinded.
Incomplete outcome data
There was no evidence of incomplete outcome data from the trial.
Three of nine included observational studies discussed either com-
plete follow up of subjects or characteristics of those lost to follow
up.
Selective reporting
None detected.
Other potential sources of bias
None detected.
Effects of interventions
See: Summary of findings for the main comparison
Antiretroviral Therapy for HIV Prevention in Serodiscordant
Couples (Part A); Summary of findings 2 Antiretroviral Therapy
for HIV Prevention in Serodiscordant Couples (Part B)
The single RCT comparing immediately treated serodiscordant
couples and delayed treatment couples showed that ART was as-
sociated with a significantly decreased risk of HIV transmission
(RR 0.04, 95% CI 0.00-0.27).
In eight of the nine cohort studies we analysed, ARTwas associated
with a decreased risk of transmission from infected index cases
to uninfected partners, ranging from rate ratios of 0.08 to 0.91.
The only cohort study that we identified that did not find this
decreased, unadjusted risk was Lu 2010, which did not provide
person time data needed to calculate a rate ratio. Using themedian
person time for both treated and untreated groups in Lu 2010, the
RR comparing treated couples with untreated couples was 1.44
(95% CI 0.85-2.44).
Meta-analysis
As there was only a single RCT, we did not combine its results with
those of the observational studies. The RR of phylogenetically
linked HIV transmissions (where the newly infected partner had
a genetically identical strain as the originally infected partner) in
this trial was 0.04 (95% CI 0.00-0.27) (Cohen 2011), yielding
a number needed to treat (NNT) of 60. Considering all HIV
transmissions to partners (virologically linked andnot virologically
linked), the RR was 0.11 (95% CI 0.04-0.32). See Figure 5 and
Figure 6.
Figure 5. Forest plot of comparison: 1 Delayed vs Immediate ART (RCTs), outcome: 1.1 Linked Incident
HIV Infection.
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Figure 6. Forest plot of comparison: 1 Delayed vs Immediate ART (RCTs), outcome: 1.2 All Incident HIV
Infection.
We performed a meta-analysis of the nine identified observational
studies to estimate the effect of ART on HIV incidence reduction
for partners of infected spouses. The summary rate ratio for all
nine studies was 0.58 [95% CI 0.35, 0.96], with substantial het-
erogeneity (I2=64%) (see Figure 7). The ten studies (9 observa-
tional studies and 1 RCT) identified 2112 episodes of HIV trans-
mission, 1016 among treated couples and 1096 among untreated
couples. To explore the potential influence of the study without
adequate person time data (Lu 2010) or monotherapy (Musicco
1994), we performed a sensitivity analysis removing the results of
these studies. The meta-analysis of the remaining seven studies
yielded a rate ratio of 0.36 [95% CI 0.17, 0.75] with substantial
heterogeneity (I2=62%) (see Figure 8). Furthermore, we analysed
the remaining seven studies with a fixed-effects model to see if
there was any consistency between the two approaches. The fixed-
effects model yielded a higher rate ratio and narrower confidence
interval [RR=0.71; 95% CI 0.63-0.81].
Figure 7. Forest plot of comparison: 2 Treated with ART vs Not Treated with ART (Observational Studies),
outcome: 2.1 Incident HIV Infection.
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Figure 8. Forest plot of comparison: 3 Treated with ART vs Not Treated with ART (Observational Studies,
sensitivity analysis), outcome: 3.1 Incident HIV Infection.
We also performed subgroup analyses to see if the effect of ART
on prevention of HIV differed by the level of CD4 in the index
partner (see Figure 9). Specifically, we categorised CD4 into three
groups-- <200 cells/µ, 200-349 cells/µL, and ≥350 cells/µL. Five
studies haddata available for subjectswhoseCD4was less than200
cells/µL (Melo 2008, Del Romero 2010, Donnell 2010, Reynolds
2011, Jia 2012), four studies had data for subjects whose CD4 was
200-349 cells/µL (Melo 2008, Del Romero 2010, Donnell 2010,
Jia 2012), and four studies had data for subjects whose CD4 was
≥350 cells/µ (Del Romero 2010, Donnell 2010, Cohen 2011,
Jia 2012). The subgroup analysis of studies with patients with
<200 cells/µL yielded a rate ratio of 0.12 [95% CI 0.02, 0.81]
with substantial heterogeneity (I2=71%). The subgroup analysis
of studies with patients with 200-349 cells/µL yielded a rate ratio
of 0.66 [95% CI 0.47, 0.92] with no heterogeneity (I2=0%). All
patients in the RCT had ≥350 CD4 cells/µL at assignment. As
noted above, that study found a rate ratio of 0.04 (95% CI 0.00-
0.27). In the three observational studies, we estimated a rate ratio
of 0.12 [95% CI 0.01, 1.99] from the subgroup analysis of ob-
servational studies with patients with ≥350 cells/µL. Excluding
the RCT, in this subgroup the total number of HIV transmissions
was 277, with 247 cases among untreated couples. In the obser-
vational studies, tests for interaction between the CD4 subgroups
were performed and yielded no statistically significant difference
between groups. Specifically, the test for interaction between the
<200 cells/µL group and the group with 200-349 cells/µL yielded
an RRR of 0.18 (95% CI 0.03-1.19). Further, when comparing
the <200 cells/µL group with the ≥350 cells/µ group, the test for
interaction yielded an RRR of 1.00 (95% CI 0.04-25.27). Finally,
a test for interaction between the group with 200-349 cells/µL and
the ≥350 cells/µ group yielded an RRR of 5.50 (95% CI 0.38-
79.25).
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Figure 9. Forest plot of comparison: 3 Treated with ART vs Not Treated with ART (< 200, 200-350, and >
350 CD4 Subgroup Analysis) (Observational Studies), outcome: 3.1 Incident HIV Infection.
Additionally, we performed a subgroup analysis of the effect of
ARTonHIVprevention by the gender of the index case (see Figure
10). Only three observational studies provided enough data to
analyse this subgroup (Del Romero 2010, Jia 2012, and Sullivan
2009). A summary estimate of the effect of ART on incident HIV
among female index cases showed a non-significant trend toward
a reduction of risk when compared to untreated female index cases
(relative risk=0.39; 95%0.13-1.18). Similarly, if a treatedmanwas
the index case, the risk of transmission was not significantly lower
when compared to untreated index male cases (relative risk=0.11;
95% CI 0.01-1.62). Tests for interaction showed no statistically
significant difference between index case subgroups (RRR=3.55,
95% CI 0.22-56.73).
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Figure 10. Forest plot of comparison: 5 Treated with ART vs Not Treated with ART (Female/Male Subgroup
Analysis) (Observational Studies), outcome: 5.1 Incident HIV Infection.
We also performed a subgroup analysis within the nine observa-
tional studies of the effect of ART on HIV prevention by income
level of the country (see Figure 11). Specifically, the effect of ART
on HIV prevention in low- and middle-income countries was es-
timated as RR=0.53 [95% CI 0.29, 0.97] with significant het-
erogeneity (I2=72%). The effect of ART on HIV prevention in
high-income countries was estimated as RR=0.77 [95% CI 0.33,
1.83] with low heterogeneity (I2=0%). Again, tests for interaction
yielded no statistically significant difference between subgroups of
income level (RRR=0.69, 95% CI 0.24-1.96).
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Figure 11. Forest plot of comparison: 5 Treated with ART vs Not Treated with ART (Subgroup Analysis:
LMIC) (Observational Studies), outcome: 5.1 Incident HIV Infection.
Severe adverse events (SAEs) have been reported from the RCT.
SAEs were not frequently reported in the observational studies.
Cohen 2011 report that 14% of participants in both the delayed
treatment arm and the early treatment arm had one or more se-
vere or life-threatening events (Grade 3 or 4), suggesting no in-
creased risk between study arms (RR=1.06; 95% CI 0.84-1.33)
(see Figure 12). The most frequent SAEs were infections, gas-
trointestinal disorders, metabolic and nutritional disorders and
psychiatric and nervous system disorders. In contrast, Grade 3
or 4 laboratory abnormalities, which most often included neu-
tropenia, abnormal phosphate levels and total bilirubin elevations,
were more likely found among participants receiving therapy early
(27%) when compared to participants receiving delayed treatment
(18%) (RR=1.49; 95% CI 1.25-1.77) (see Figure 13). Among the
observational studies, Del Romero 2010 reported that genitouri-
nary infections occurred in 8/144 treated couples (6%) and 62/
388 among untreated couples (16%) during follow up. Lu 2010
reported that 266 (19%) of 1369 treated couples switched ARTs.
Nearly all couples who switched (n=259; 97%) did so as a result
of adverse events, while three other patients developed resistance.
Figure 12. Forest plot of comparison: 1 Delayed vs Immediate ART (RCTs), outcome: 1.3 Severe or Life-
Threatening Adverse Events (Grade 3 or 4).
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Figure 13. Forest plot of comparison: 1 Delayed vs Immediate ART (RCTs), outcome: 1.4 Grade 3 or 4
Laboratory Abnormalities.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Antiretroviral Therapy for HIV Prevention in Serodiscordant Couples (Part B)
Patient or population: Serodiscordant couples
Settings: Botswana, Brazil, China, Italy, Kenya, Rwanda, South Africa, Spain, Tanzania, Uganda, and Zambia
Intervention: Antiretroviral Therapy
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Antiretroviral therapy
HIV incidence: gen-
der subgroup (female
cases)
74 per 10001,2 29 per 1000
(10 to 88)2
RR 0.39
(0.13 to 1.18)
15608
(3 studies)
⊕⊕©©
low3,4
Observational studies
only
HIV incidence: gender
subgroup (male Cases)
48 per 10001,2 5 per 1000
(0 to 78)1,2
RR 0.11
(0.01 to 1.62)
25073
(3 studies)
⊕⊕©©
low3,4
Observational studies
only
HIV incidence: low-/mid-
dle-income countries
54 per 10001,2 29 per 1000
(16 to 53)1,2
RR 0.53
(0.29 to 0.97)
45029
(7 studies)
⊕⊕©©
low3,5
Observational studies
only
HIV incidence: high in-
come countries
31 per 10001,2 24 per 1000
(10 to 57)1,2
RR 0.77
(0.33 to 1.83)
1061
(2 studies)
⊕©©©
very low3
Observational studies
only
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
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Very low quality: We are very uncertain about the estimate.
1 Numerators and denominators taken from text where possible. Numbers were not used to calculate the relative effect estimates.
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D I S C U S S I O N
Summary of main results
We found that ART was associated with decreased risk of trans-
mission ofHIV in discordant couples. This intervention effect was
particularly pronounced in the one largemulticentre RCT that has
been completed but also appeared in several observational studies
that had adjusted for a variety of cofactors for transmission. Inter-
estingly, the largely historical analyses of Musicco 1994 and Del
Romero 2010 of patients on monotherapy and dual therapy even
found pronounced independent protective effects for ART. More
recent observational studies, such as Sullivan 2009, Donnell 2010,
and Reynolds 2011, have found even larger effects than these ear-
lier studies, suggesting that more potent ART regimens are associ-
ated with even greater reductions in transmission, though Jia 2012
and Birungi 2012 found less pronounced reductions in transmis-
sion. Only one observational study found an increased risk, al-
beit statistically non-significant, of HIV transmission among ART
treated couples compared to untreated couples (Lu 2010). The
authors’ study objective was not to examine the effect of ART in
serodiscordant couples but rather to estimate HIV incidence and
clinical progression, quality of life and behavioural risk factors.
Unpublished data suggest that the treated couples were followed
for nearly three times longer than untreated couples (3532 years
and 1385 years, respectively), thus, possibly allowing for more op-
portunity for infection among the treated couples. Nevertheless,
it should be noted that the authors found no difference in rates
of HIV transmission between ART-treated couples (4.8%) and
untreated couples (3.2%). A later analysis, also from China (Jia
2012), did find a statistically significant decreased risk of transmis-
sion in treated couples compared to untreated couples. It should
be noted that Jia 2012 reported on all serodiscordant couples in
China who test HIV-positive at the National Center for AIDS/
STD Control and Prevention at the Chinese Center for Disease
Control and Prevention from 2003-2011, while Lu 2010 reported
on serodiscordant couples reporting to a local subsidiary office of
the National Center for AIDS/STDControl and Prevention from
2006-2008. As such, it is likely that Jia 2012 has re-analyzed some
of the same serodiscordant couples as Lu 2010, another possibility
we considered when performing the sensitivity analysis by remov-
ing Lu 2010 data from our overall effect.
We explored the effect of ART on transmission risk of HIV in
discordant couples in CD4 subgroup analyses to see if the effect
differed by CD4 stratum. Unfortunately, most observational stud-
ies did not report risk of HIV transmission stratified by the index
case’s baseline CD4. Data from HPTN 052 clearly demonstrate
the large and positive benefit among index partners with between
350 and 550 CD4 cells/µL (Grinsztejn 2011).
It is important to note that participants in this study were long-
term couples, and, as such, they do not represent all situations
in which transmission risk exists. Transmission during the acute
phase of HIV infection is an important contributor to overall
incidence (Miller 2010) and would not be averted by the couples
counseling and partner therapy discussed in this review.
Several relevant studies are in progress. Please see Appendix 4.
Overall completeness and applicability of
evidence
HPTN 052 provides clear and compelling evidence of benefit for
treating index participants with between 350 and 550 CD4 cells/
µL. Other data we examined that bear on the benefit of therapy
are from partnerships where the index participants had <350 CD4
cells/µL, and unmeasured confounding remains a significant issue
in these cohort studies. Given that we did not conduct an individ-
ual patient database meta-analysis for the observational studies, we
were unable to control for a variety of cofactors, such as number of
exposures, circumcision, HIV viral load, sexually transmitted in-
fections, condomuse or potency of ART.Nonetheless, the strength
and consistency of the evidence and the evidence contributed by
the large, high-quality RCT argue strongly in favour of a potent
biological effect of ART on reducing risk of HIV transmission in
discordant couples.
We found no studies that explored outcomes such as the acquisi-
tion of primary drug resistant HIV by previously uninfected part-
ners, HIV-related mortality,HIV-related morbidity and quality of
life, although subsequent publications from the HPTN 052 trial
will likely shed light on these outcomes. Because the vast majority
of the couples in the included studies were heterosexual, the find-
ings of this review may not be generalisable to populations of men
who have sex withmen. Other concerns thatmust be addressed are
the additional financial costs of recommending ART for preven-
tion,whichwouldmake implementationdifficult if not impossible
in many resource-constrained settings. There is also the potential
for significant implementation and adherence challenges if ART
is offered earlier to discordant couples (e.g., expanding treatment
indications) when large numbers of patients that meet clinical or
immunologic criteria for treatment are remain untreated.
Quality of the evidence
GRADE
In the GRADE system, well-conducted RCTs (without additional
limitations) provide high quality evidence, and observational stud-
ies without any special strengths (and without additional limita-
tions) provide low-quality evidence. The quality of evidence pro-
vided by a body of literature comprised exclusively of observational
studies would thus be graded as “low.” In this analysis, we found
that the quality of evidence was high, based on the large effect size
found in the RCT, the biological plausibility of the relationship
and the strength, temporality and the consistency of this relation-
ship in the supporting observational studies. Please see Summary
of findings for the main comparison and Summary of findings 2
for details.
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Potential biases in the review process
Biases in the review process were minimised by not limiting the
search by language, by performing a comprehensive search of
databases and conference proceedings and by contacting experts
in the field for unpublished and ongoing studies. We explored
publication bias for the observational studies by using funnel plots
(see Figure 14 and Figure 15). Based on only nine studies, it is
difficult to adequately assess publication bias. However, Figure 14
may suggest publication bias, but the assymetry in the plot could
also be an artefact of the true effect size differences between high
precision studies and low precision studies. Furthermore, RR data
were not available for all studies, which in turn could have influ-
enced these estimated effect sizes.
Figure 14. Funnel plot of comparison: 1 Treated with ART vs Not Treated with ART (Observational
Studies), outcome: 2.1 Incident HIV Infection.
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Figure 15. Funnel plot of comparison: 2 Treated with ART vs Not Treated with ART (Observational
Studies, sensitivity analysis), outcome: 3.1 Incident HIV Infection.
Agreements and disagreements with other
studies or reviews
Our findings are consistent with those of another recent review
(Attia 2009).
The review by Attia and colleagues (Attia 2009) was focused dif-
ferently than ours. The objective of Attia 2009 was to estimate
HIV transmission rates among serodiscordant couples with var-
ious treatment experience, while our review’s objective is to es-
timate the pooled risk of transmission, comparing ART-treated
couples with ART-untreated couples. Attia 2009 includes three
types of studies: a) studies of only ART-treated couples, b) studies
of only untreated couples, and c) studies of both ART-treated and
untreated couples. Our review includes only studies with both
ART-treated and untreated couples. Four of the studies identified
in our review were also included in Attia 2009: Castilla 2005 (Del
Romero 2010), Melo 2008, Reynolds 2011, and Sullivan 2009.
No formal assessment of evidence quality was performed in Attia
2009.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
From the evidence provided by one RCT and nine observational
studies, ART has been shown be a potent intervention for preven-
tion of HIV in discordant couples. In 2012 WHO issued guide-
lines on serodiscordant couples to recommend that the partner
living with HIV be offered ART regardless of CD4 count (WHO
2012). Patients in discordant couples beginning ART should be
counselled that adherence to ART can also reduce their risk of
transmitting HIV to their partners. A policy question remaining
to be addressed is how much effort should be focused on treat-
ing individuals with ≥350 CD4 cells/µL when access to ART for
persons with <350 CD4 cells/µL is far from universal. Significant
questions remain about durability of protection, cumulative an-
tiretroviral toxicity, when to start treating an infected partner (for
instance, at diagnosis or at a specific CD4 or plasma viral load
level) and transmission of ART-resistant strains to partners.
The success of this intervention likely relies on good adherence,
especially in stable couples. Programmes should be designed that
include counselling, support, follow up and mutual disclosure,
as these components may have a role in supporting adherence.
In addition to ART provision, limitations in resources needed to
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implement such expanded ART indications must be addressed.
Implications for research
Additional data are needed on durability of protection for unin-
fected partners, adverse events associated with earlier initiation of
ART, including effects of longer-term ART, the potential for ear-
lier development of antiretroviral resistance (resulting in a need
to change regimens prematurely) and HIV morbidity, quality of
life and the potential for risk compensation. Not only are there
are multiple opportunities to examine these issues in existing co-
horts, but there are several RCTs underway that will likely help
strengthen the observational evidence.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Birungi 2012
Methods Observational cohort
Participants 550 heterosexual couples attending a clinic in Uganda
Interventions ART
Outcomes Incident HIV Infection
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Non-randomised study
Allocation concealment (selection bias) High risk Non-randomised study
Blinding (performance bias and detection
bias)
All outcomes
High risk Non-randomised study
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Study protocol was not available. Risk of bias unclear.
Selective reporting (reporting bias) Unclear risk Study protocol was not available. Risk of bias unclear.
Other bias Unclear risk No statement
Cohen 2011
Methods Randomised controlled trial
Participants 1750 serodiscordant couples enrolled in nine countries with CD4 counts from 350-550
cells/µL
Interventions Immediate ART vs delayed ART until CD4 falls below 250
Outcomes Incident HIV infection (all and virologically linked)
Notes
Risk of bias
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Cohen 2011 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The method of sequence generation is not explicitly
stated but as permuted block randomisation with stratifi-
cation was used, it is assumed this was done by computer
and we judged it to be at low risk of bias
Allocation concealment (selection bias) Unclear risk Random allocation in a 1:1 ratio was performed in the
RCT. The article does not specify how allocation was
concealed
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Unblinded study but biological endpoints make bias less
likely
Incomplete outcome data (attrition bias)
All outcomes
Low risk No evidence of attrition bias.
Selective reporting (reporting bias) Low risk No evidence of reporting bias.
Other bias Low risk No evidence of other bias.
Del Romero 2010
Methods Observational cohort
Participants 648 heterosexual couples attending a clinic in Madrid, Spain, from 1989 to 2008
Interventions ART
Outcomes Incident HIV Infection
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Non-randomised study
Allocation concealment (selection bias) High risk Non-randomised study
Blinding (performance bias and detection
bias)
All outcomes
High risk Non-randomised study
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Del Romero 2010 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete follow-up. All subjects accounted for.
Selective reporting (reporting bias) Low risk No evidence of reporting bias.
Other bias Low risk No evidence of other bias.
Donnell 2010
Methods Observational cohort
Participants Heterosexual African adults who were seropositive for both HIV and herpes simplex
virus type II (HSV-2) and their HIV-uninfected sexual partners. Three thousand four
hundred eight couples were enrolled from seven countries (Botswana, Kenya, Rwanda,
South Africa, Tanzania, Uganda, and Zambia)
Interventions ART
Outcomes Incident HIV Infection
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Non-randomised study
Allocation concealment (selection bias) High risk Non-randomised study
Blinding (performance bias and detection
bias)
All outcomes
High risk Non-randomised study
Incomplete outcome data (attrition bias)
All outcomes
Low risk Subjects lost to follow up discussed.
Selective reporting (reporting bias) Low risk No evidence of reporting bias.
Other bias Low risk No evidence of other bias.
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Jia 2012
Methods National-level data of HIV testing and treatment from the National Centre for AIDS/
STD Control and Prevention
Participants All individuals in China who have tested positive for HIV
Interventions ART
Outcomes HIV incidence
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Non-randomised study
Allocation concealment (selection bias) High risk Non-randomised study
Blinding (performance bias and detection
bias)
All outcomes
High risk Non-randomised study
Incomplete outcome data (attrition bias)
All outcomes
Low risk Subjects lost to follow up or with missing
data were discussed
Selective reporting (reporting bias) Unclear risk Study protocol was not available. Risk of
bias unclear.
Other bias Unclear risk No statement
Lu 2010
Methods Observational cohort
Participants 1927 heterosexual couples between January 2006 and December 2008 for testing and
treatment at county hospitals in China
Interventions ART
Outcomes Incident HIV Infection
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Lu 2010 (Continued)
Random sequence generation (selection
bias)
High risk Non-randomised study
Allocation concealment (selection bias) High risk Non-randomised study
Blinding (performance bias and detection
bias)
All outcomes
High risk Non-randomised study
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Study protocol was not available. Risk of bias unclear.
Selective reporting (reporting bias) Unclear risk Study protocol was not available. Risk of bias unclear.
Other bias Low risk Though unknown in what direction, bias is potentially present
as a result of unavailable person-time data for treated and un-
treated couples
Melo 2008
Methods Observational cohort
Participants 93 discordant couples, in which the female member of the couple was infected in 67
(72%) and the male in 26 (28%)
Interventions ART
Outcomes Incident HIV Infection
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Non-randomised study
Allocation concealment (selection bias) High risk Non-randomised study
Blinding (performance bias and detection
bias)
All outcomes
High risk Non-randomised study
Incomplete outcome data (attrition bias)
All outcomes
Low risk Subjects lost to follow up discussed.
Selective reporting (reporting bias) Low risk No evidence of reporting bias.
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Melo 2008 (Continued)
Other bias Low risk No evidence of other bias.
Musicco 1994
Methods Observational cohort
Participants A cohort of 436 monogamous HIV-uninfected female sexual partners of HIV-infected
men recruited from 16 centres in Italy
Interventions Zidovudine
Outcomes Incident HIV Infection
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Non-randomised study
Allocation concealment (selection bias) High risk Non-randomised study
Blinding (performance bias and detection
bias)
All outcomes
High risk Non-randomised study
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Study protocol was not available. Risk of bias unclear.
Selective reporting (reporting bias) Low risk No evidence of reporting bias.
Other bias Low risk No evidence of other bias.
Reynolds 2011
Methods Observational cohort
Participants 250 HIV-discordant couples from Rakai, Uganda.
Interventions ART
Outcomes Incident HIV Infection
Notes
Risk of bias
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Reynolds 2011 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Non-randomised study
Allocation concealment (selection bias) High risk Non-randomised study
Blinding (performance bias and detection
bias)
All outcomes
High risk Non-randomised study
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Study protocol was not available. Risk of bias unclear.
Selective reporting (reporting bias) Low risk No evidence of reporting bias.
Other bias Low risk No evidence of other bias.
Sullivan 2009
Methods Observational cohort
Participants 2,993 HIV-discordant couples in Rwanda and Zambia followed from 2002 to 2008
Interventions ART
Outcomes Incident HIV Infection
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Non-randomised study
Allocation concealment (selection bias) High risk Non-randomised study
Blinding (performance bias and detection
bias)
All outcomes
High risk Non-randomised study
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Study protocol was not available. Risk of bias unclear.
Selective reporting (reporting bias) Low risk No evidence of reporting bias.
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Sullivan 2009 (Continued)
Other bias Low risk No evidence of other bias.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Baeten 2010 ART was not given
Barreiro 2006 All index cases received ART
Brill 2003 ART was not given
Bunnell 2006 All index cases received ART
Bunnell 2008 All index cases received ART
Fideli 2001 ART was not given
Gray 2001 ART was not given
Kayitenkore 2006 ART was not given
Mehendale 2004 ART was not given
Operskalski 1997 ART was not given
Peters 2008 ART was not given
Peterson 2007 ART was not given
Quinn 2000 ART was not given
Ragni 1998 ART was not given
Tovanabutra 2002 ART was not given
Wawer 2005 ART was not given
39Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D A T A A N D A N A L Y S E S
Comparison 1. Delayed vs Immediate ART (RCTs)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Linked Incident HIV Infection 1 Rate Ratio (Fixed, 95% CI) 0.04 [0.00, 0.27]
2 All Incident HIV Infection 1 Rate Ratio (Fixed, 95% CI) 0.11 [0.04, 0.32]
3 Severe or Life-Threatening
Adverse Events (Grade 3 or 4)
1 1763 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.84, 1.33]
4 Grade 3 or 4 Laboratory
Abnormalities
1 1763 Risk Ratio (M-H, Fixed, 95% CI) 1.49 [1.25, 1.77]
Comparison 2. Treated with ART vs Not Treated with ART (Observational Studies)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incident HIV Infection 9 Rate Ratio (Random, 95% CI) 0.58 [0.35, 0.96]
Comparison 3. Treated with ART vs Not Treated with ART (Observational Studies, sensitivity analysis)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incident HIV Infection 7 Rate Ratio (Random, 95% CI) 0.36 [0.17, 0.75]
Comparison 4. Treated with ART vs Not Treated with ART (< 200, 200-349, and ≥350 CD4 Cells/µL Subgroup
Analysis) (Observational Studies)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incident HIV Infection 5 Rate Ratio (Random, 95% CI) Subtotals only
1.1 Less than 200 CD4 5 Rate Ratio (Random, 95% CI) 0.12 [0.02, 0.81]
1.2 200-350 CD4 4 Rate Ratio (Random, 95% CI) 0.66 [0.47, 0.92]
1.3 More than 350 CD4 3 Rate Ratio (Random, 95% CI) 0.12 [0.01, 1.99]
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Comparison 5. Treated with ART vs Not Treated with ART (Female/Male Subgroup Analysis) (Observational
Studies)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incident HIV Infection 3 Risk Ratio (Random, 95% CI) Subtotals only
1.1 Female Index Case 3 Risk Ratio (Random, 95% CI) 0.39 [0.13, 1.18]
1.2 Male Index Case 3 Risk Ratio (Random, 95% CI) 0.11 [0.01, 1.62]
Comparison 6. Treated with ART vs Not Treated with ART (Subgroup Analysis: Low-/Middle-Income vs High-
income)) (Observational Studies)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incident HIV Infection 9 Rate Ratio (Random, 95% CI) Subtotals only
1.1 Low/Middle Income
Country
7 Rate Ratio (Random, 95% CI) 0.53 [0.29, 0.97]
1.2 High Income Country 2 Rate Ratio (Random, 95% CI) 0.77 [0.33, 1.83]
Analysis 1.1. Comparison 1 Delayed vs Immediate ART (RCTs), Outcome 1 Linked Incident HIV Infection.
Review: Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples
Comparison: 1 Delayed vs Immediate ART (RCTs)
Outcome: 1 Linked Incident HIV Infection
Study or subgroup log [Rate Ratio] Rate Ratio Weight Rate Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Cohen 2011 -3.3077 (1.02) 100.0 % 0.04 [ 0.00, 0.27 ]
Total (95% CI) 100.0 % 0.04 [ 0.00, 0.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.24 (P = 0.0012)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 1.2. Comparison 1 Delayed vs Immediate ART (RCTs), Outcome 2 All Incident HIV Infection.
Review: Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples
Comparison: 1 Delayed vs Immediate ART (RCTs)
Outcome: 2 All Incident HIV Infection
Study or subgroup log [Rate Ratio] Rate Ratio Weight Rate Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Cohen 2011 -2.18 (0.53) 100.0 % 0.11 [ 0.04, 0.32 ]
Total (95% CI) 100.0 % 0.11 [ 0.04, 0.32 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.11 (P = 0.000039)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 1.3. Comparison 1 Delayed vs Immediate ART (RCTs), Outcome 3 Severe or Life-Threatening
Adverse Events (Grade 3 or 4).
Review: Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples
Comparison: 1 Delayed vs Immediate ART (RCTs)
Outcome: 3 Severe or Life-Threatening Adverse Events (Grade 3 or 4)
Study or subgroup Early Therapy Delayed Therapy Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cohen 2011 127/886 119/877 100.0 % 1.06 [ 0.84, 1.33 ]
Total (95% CI) 886 877 100.0 % 1.06 [ 0.84, 1.33 ]
Total events: 127 (Early Therapy), 119 (Delayed Therapy)
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.64)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours early treatment Favours delayed treatment
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Analysis 1.4. Comparison 1 Delayed vs Immediate ART (RCTs), Outcome 4 Grade 3 or 4 Laboratory
Abnormalities.
Review: Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples
Comparison: 1 Delayed vs Immediate ART (RCTs)
Outcome: 4 Grade 3 or 4 Laboratory Abnormalities
Study or subgroup Early Therapy Delayed Therapy Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cohen 2011 242/886 161/877 100.0 % 1.49 [ 1.25, 1.77 ]
Total (95% CI) 886 877 100.0 % 1.49 [ 1.25, 1.77 ]
Total events: 242 (Early Therapy), 161 (Delayed Therapy)
Heterogeneity: not applicable
Test for overall effect: Z = 4.42 (P < 0.00001)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours early treatment Favours delayed treatment
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Analysis 2.1. Comparison 2 Treated with ART vs Not Treated with ART (Observational Studies), Outcome
1 Incident HIV Infection.
Review: Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples
Comparison: 2 Treated with ART vs Not Treated with ART (Observational Studies)
Outcome: 1 Incident HIV Infection
Study or subgroup log [Rate Ratio] Rate Ratio Weight Rate Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Musicco 1994 -0.13 (0.46) 14.1 % 0.88 [ 0.36, 2.16 ]
Melo 2008 -2.33 (1.45) 2.8 % 0.10 [ 0.01, 1.67 ]
Sullivan 2009 -1.58 (0.51) 12.8 % 0.21 [ 0.08, 0.56 ]
Del Romero 2010 -1.58 (1.48) 2.7 % 0.21 [ 0.01, 3.75 ]
Lu 2010 (1) 0.363 (0.27) 19.9 % 1.44 [ 0.85, 2.44 ]
Donnell 2010 -2.53 (1) 5.3 % 0.08 [ 0.01, 0.57 ]
Reynolds 2011 -2.29 (1.42) 2.9 % 0.10 [ 0.01, 1.64 ]
Birungi 2012 -0.0943 (0.45) 14.4 % 0.91 [ 0.38, 2.20 ]
Jia 2012 (2) -0.3011051 (0.065) 25.1 % 0.74 [ 0.65, 0.84 ]
Total (95% CI) 100.0 % 0.58 [ 0.35, 0.96 ]
Heterogeneity: Tau2 = 0.26; Chi2 = 22.32, df = 8 (P = 0.004); I2 =64%
Test for overall effect: Z = 2.12 (P = 0.034)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours experimental Favours control
(1) Estimated from median follow-up time.
(2) Hazard Ratio
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Analysis 3.1. Comparison 3 Treated with ART vs Not Treated with ART (Observational Studies, sensitivity
analysis), Outcome 1 Incident HIV Infection.
Review: Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples
Comparison: 3 Treated with ART vs Not Treated with ART (Observational Studies, sensitivity analysis)
Outcome: 1 Incident HIV Infection
Study or subgroup log [Rate Ratio] Rate Ratio Weight Rate Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Birungi 2012 -0.0943 (0.45) 21.9 % 0.91 [ 0.38, 2.20 ]
Del Romero 2010 -1.58 (1.48) 5.4 % 0.21 [ 0.01, 3.75 ]
Donnell 2010 -2.53 (1) 9.9 % 0.08 [ 0.01, 0.57 ]
Jia 2012 (1) -0.3011051 (0.065) 31.4 % 0.74 [ 0.65, 0.84 ]
Melo 2008 -2.33 (1.45) 5.6 % 0.10 [ 0.01, 1.67 ]
Reynolds 2011 -2.29 (1.42) 5.8 % 0.10 [ 0.01, 1.64 ]
Sullivan 2009 -1.58 (0.51) 20.1 % 0.21 [ 0.08, 0.56 ]
Total (95% CI) 100.0 % 0.36 [ 0.17, 0.75 ]
Heterogeneity: Tau2 = 0.45; Chi2 = 15.83, df = 6 (P = 0.01); I2 =62%
Test for overall effect: Z = 2.72 (P = 0.0064)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
(1) Hazard Ratio
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Analysis 4.1. Comparison 4 Treated with ART vs Not Treated with ART (< 200, 200-349, and ≥350 CD4
Cells/µL Subgroup Analysis) (Observational Studies), Outcome 1 Incident HIV Infection.
Review: Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples
Comparison: 4 Treated with ART vs Not Treated with ART (< 200, 200-349, and≥350 CD4 Cells/ L Subgroup Analysis) (Observational Studies)
Outcome: 1 Incident HIV Infection
Study or subgroup log [Rate Ratio] Rate Ratio Weight Rate Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Less than 200 CD4
Del Romero 2010 (1) -1.83 (1.42) 18.7 % 0.16 [ 0.01, 2.59 ]
Donnell 2010 -6.91 (1.9) 14.2 % 0.00 [ 0.00, 0.04 ]
Jia 2012 (2) -0.478 (0.1218438) 31.0 % 0.62 [ 0.49, 0.79 ]
Melo 2008 (3) -1.2 (1.55) 17.4 % 0.30 [ 0.01, 6.28 ]
Reynolds 2011 (4) -2.29 (1.42) 18.7 % 0.10 [ 0.01, 1.64 ]
Subtotal (95% CI) 100.0 % 0.12 [ 0.02, 0.81 ]
Heterogeneity: Tau2 = 3.02; Chi2 = 14.02, df = 4 (P = 0.01); I2 =71%
Test for overall effect: Z = 2.17 (P = 0.030)
2 200-350 CD4
Del Romero 2010 (5) -2.3 (1.29) 1.8 % 0.10 [ 0.01, 1.26 ]
Donnell 2010 -0.43 (0.97) 3.1 % 0.65 [ 0.10, 4.35 ]
Jia 2012 (6) -0.371 (0.1768233) 93.7 % 0.69 [ 0.49, 0.98 ]
Melo 2008 (7) -1.11 (1.46) 1.4 % 0.33 [ 0.02, 5.76 ]
Subtotal (95% CI) 100.0 % 0.66 [ 0.47, 0.92 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.42, df = 3 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 2.44 (P = 0.015)
3 More than 350 CD4
Del Romero 2010 (8) -1.77 (1.45) 32.5 % 0.17 [ 0.01, 2.92 ]
Donnell 2010 -6.91 (2.55) 19.1 % 0.00 [ 0.00, 0.15 ]
Jia 2012 (9) -0.446 (0.2222947) 48.3 % 0.64 [ 0.41, 0.99 ]
Subtotal (95% CI) 100.0 % 0.12 [ 0.01, 1.99 ]
Heterogeneity: Tau2 = 4.18; Chi2 = 7.13, df = 2 (P = 0.03); I2 =72%
Test for overall effect: Z = 1.48 (P = 0.14)
0.01 0.1 1 10 100
Favours experimental Favours control
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(1) Risk ratio.
(2) HR; CD4 < 250
(3) 0/8 treated subjects whose CD4 < 350. Risk Ratio.
(4) All subjects < 250 CD4.
(5) Risk ratio.
(6) HR; CD4 250-349
(7) 0/8 treated subjects whose CD4 < 350. Risk Ratio.
(8) Risk ratio.
(9) HR; CD4 350-550
Analysis 5.1. Comparison 5 Treated with ART vs Not Treated with ART (Female/Male Subgroup Analysis)
(Observational Studies), Outcome 1 Incident HIV Infection.
Review: Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples
Comparison: 5 Treated with ART vs Not Treated with ART (Female/Male Subgroup Analysis) (Observational Studies)
Outcome: 1 Incident HIV Infection
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Female Index Case
Del Romero 2010 -3.51 (1.27) 14.3 % 0.03 [ 0.00, 0.36 ]
Jia 2012 -0.315 (0.09770211) 50.4 % 0.73 [ 0.60, 0.88 ]
Sullivan 2009 (1) -0.8 (0.53) 35.3 % 0.45 [ 0.16, 1.27 ]
Subtotal (95% CI) 100.0 % 0.39 [ 0.13, 1.18 ]
Heterogeneity: Tau2 = 0.62; Chi2 = 7.04, df = 2 (P = 0.03); I2 =72%
Test for overall effect: Z = 1.67 (P = 0.095)
2 Male Index Case
Del Romero 2010 -2.66 (0.98) 37.9 % 0.07 [ 0.01, 0.48 ]
Jia 2012 -0.288 (0.09098851) 47.1 % 0.75 [ 0.63, 0.90 ]
Sullivan 2009 (2) -6.91 (2.9) 15.0 % 0.00 [ 0.00, 0.29 ]
Subtotal (95% CI) 100.0 % 0.11 [ 0.01, 1.62 ]
Heterogeneity: Tau2 = 3.91; Chi2 = 10.99, df = 2 (P = 0.004); I2 =82%
Test for overall effect: Z = 1.60 (P = 0.11)
0.01 0.1 1 10 100
Favours experimental Favours control
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(1) Estimate is a rate ratio.
(2) Estimate is a rate ratio.
Analysis 6.1. Comparison 6 Treated with ART vs Not Treated with ART (Subgroup Analysis: Low-/Middle-
Income vs High-income)) (Observational Studies), Outcome 1 Incident HIV Infection.
Review: Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples
Comparison: 6 Treated with ART vs Not Treated with ART (Subgroup Analysis: Low-/Middle-Income vs High-income)) (Observational Studies)
Outcome: 1 Incident HIV Infection
Study or subgroup log [Rate Ratio] Rate Ratio Weight Rate Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Low/Middle Income Country
Birungi 2012 -0.0943 (0.45) 17.7 % 0.91 [ 0.38, 2.20 ]
Donnell 2010 -2.53 (1) 7.1 % 0.08 [ 0.01, 0.57 ]
Jia 2012 (1) -0.3011051 (0.065) 28.0 % 0.74 [ 0.65, 0.84 ]
Lu 2010 (2) 0.363 (0.27) 23.3 % 1.44 [ 0.85, 2.44 ]
Melo 2008 -2.33 (1.45) 3.9 % 0.10 [ 0.01, 1.67 ]
Reynolds 2011 -2.29 (1.42) 4.1 % 0.10 [ 0.01, 1.64 ]
Sullivan 2009 -1.58 (0.51) 16.0 % 0.21 [ 0.08, 0.56 ]
Subtotal (95% CI) 100.0 % 0.53 [ 0.29, 0.97 ]
Heterogeneity: Tau2 = 0.34; Chi2 = 21.43, df = 6 (P = 0.002); I2 =72%
Test for overall effect: Z = 2.05 (P = 0.040)
2 High Income Country
Del Romero 2010 -1.58 (1.48) 8.8 % 0.21 [ 0.01, 3.75 ]
Musicco 1994 -0.13 (0.46) 91.2 % 0.88 [ 0.36, 2.16 ]
Subtotal (95% CI) 100.0 % 0.77 [ 0.33, 1.83 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.88, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 0.59 (P = 0.56)
0.01 0.1 1 10 100
Favours experimental Favours control
(1) Hazard Ratio
(2) Estimated from median follow-up time.
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A P P E N D I C E S
Appendix 1. Example of search strategy used in PubMed (modified as needed for use in the other
databases)
Search PubMed search strategy
#5 Search (((#16) AND #17) AND #18) AND #19 Limits: Publication Date from 1987/01/01 to 2012/08/31
#4 Search (randomised controlled trial[pt] OR controlled clinical trial[pt] OR randomised controlled trials[mh] OR random
allocation[mh] ORdouble-blind method[mh]OR single-blindmethod[mh]OR clinical trial[pt]OR clinical trials[mh]OR
(“clinical trial”[tw]) OR ((singl*[tw] OR doubl*[tw] OR trebl*[tw] OR tripl*[tw]) AND (mask*[tw] OR blind*[tw])) OR
placebos[mh] OR placebo*[tw] OR random*[tw] OR non-randomi*[tw] OR before after study[tw] OR time series[tw] OR
“case control”[tw] OR prospective*[tw] OR retrospective*[tw] OR cohort[tw] OR cross-section*[tw] OR prospective[tw]
OR retrospective[tw] OR research design [mh:noexp] OR comparative study[mh] OR evaluation studies[mh] OR follow-
up studies[mh] OR prospective studies[mh] OR control*[tw] OR prospectiv*[tw] OR volunteer*[tw] OR longitud*[tw]
OR descripti*[tiab] OR study[tiab] OR evaluat*[tiab] OR “odds ratio”[tw] OR “hazard ratio”[tw] OR “relative risk”[tw]
OR “risk ratio”[tw] OR “rate ratio”[tw] OR AOR[tw] OR RRR[tw] OR NNT[tw])
#3 Search (Couples[tiab] OR (sex*[tiab] AND partner*[tiab]) OR husband[tiab] OR wife[tiab] OR boyfriend*[tiab] OR
girlfriend*[tiab] OR spouse*[tiab] OR dyad*[tiab] OR married[tiab] OR marital[tiab] OR “Marriage”[Mesh] OR
“Spouses”[Mesh] OR serodiscord*[tiab] OR sero-discord*[tiab] OR discord*[tiab])
#2 Search (HAART[tiab] OR ART[tiab] OR ARV[tiab] OR ARVs[tiab] OR antiretroviral[tiab] OR anti-retroviral[tiab] OR
anti-viral[tiab] OR antiviral[tiab] OR “Antiretroviral Therapy, Highly Active”[Mesh] OR “Anti-Retroviral Agents”[Mesh])
#1 Search (HIV Infections[MeSH] OR HIV[MeSH] OR hiv[tiab] OR hiv-1[tiab] OR hiv-2*[tiab] OR hiv1[tiab] OR
hiv2[tiab] OR hiv infect*[tiab] OR human immunodeficiency virus[tiab] OR human immune deficiency virus[tiab] OR
human immuno-deficiency virus[tiab] OR human immune-deficiency virus[tiab] OR ((human immun*) AND (deficiency
virus[tiab])) OR acquired immunodeficiency syndromes[tiab] OR acquired immune deficiency syndrome[tiab] OR ac-
quired immuno-deficiency syndrome[tiab] OR acquired immune-deficiency syndrome[tiab] OR ((acquired immun*) AND
(deficiency syndrome[tiab])) or “sexually transmitted diseases, viral”[mh]) OR HIV[tiab] OR HIV/AIDS[tiab] OR HIV-
infected[tiab] OR HIV[title] OR HIV/AIDS[title] OR HIV-infected[title])
Appendix 2. Search terms and yield in searching conference abstract archives
It was not possible to perform complex searches of conference abstract archives. Instead, we used a variety of relevant terms, individually
and in simple combinations.
AEGIS search strategy and results
Conferences included:
• British HIV/AIDS Association, 2001-2008
• Conference on Retroviruses and Opportunistic Infections (CROI), 1994-2008
• European AIDS Society Conference, 2001 and 2003
• International AIDS Society, Conference on HIV Pathogenesis, Treatment and Prevention (IAS), 2001-2005
• International AIDS Society, International AIDS Conference (IAC), 1985-2004
• US National HIV Prevention Conference, 1999, 2003, and 2005
Strategy:
(antiretroviral OR anti-retroviral) AND (discordant OR serodiscordant OR sero-discordant OR HIV-discordant)
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• total results: n=178
• reviewed closely and excluded: n=4
• included: n=0
IAC/IAS and CROI search terms and results:
• Discordant
• “HIV-discordant”
• Serodiscordant
• “Sero-discordant”
Previous version of review (searching IAC/IAS, 2006-2010; CROI, 2009-2011)
• total results: n=516
• reviewed closely and excluded: n=0
• included: n=0
Current version of review (searching IAC 2012; CROI, 2012)
• total results: n=168
• reviewed closely and excluded: n=0
• included: n=2 (One of these, Jia 2012, was subsequently published in a peer-reviewed journal, and we refer in this review to the
published version.)
Appendix 3. Newcastle Ottawa Quality Assessment Scale
COHORT STUDIES (Newcastle-Ottawa)
Note: A study can be awarded a maximum of one star for each numbered item within the Selection and Outcome categories. A
maximum of two stars can be given for Comparability
Selection
1) Representativeness of the exposed cohort
a) truly representative of the average treated serodiscordant couple in the community
b) somewhat representative of the average treated serodiscordant couple in the community
c) selected group of users eg nurses, volunteers, HIV clinic patients
d) no description of the derivation of the cohort
2) Selection of the non exposed cohort
a) drawn from the same community as the exposed cohort
b) drawn from a different source
c) no description of the derivation of the non exposed cohort
3) Ascertainment of exposure
a) secure record (eg surgical records)
b) structured interview
c) written self report
d) no description
4) Demonstration that outcome of interest was not present at start of study
a) yes
b) no
Comparability
1) Comparability of cohorts on the basis of the design or analysis
a) study controls for or matches on disease status when comparing treated and untreated couples
b) study controls for any additional factor ? (e.g. age or sex)
Outcome
1) Assessment of outcome
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a) independent blind assessment
b) record linkage
c) self report
d) no description
2) Was follow-up long enough for outcomes to occur
a) yes (select an adequate follow up period for outcome of interest)
b) no
3) Adequacy of follow up of cohorts
a) complete follow up - all subjects accounted for
b) subjects lost to follow up unlikely to introduce bias - small number lost - > 79% (select an adequate %)
follow up, or description provided of those lost)
c) follow up rate < 20% (select an adequate %) and no description of those lost
d) no statement
NOS - CODING MANUAL FOR COHORT STUDIES
SELECTION
1) Representativeness of the Exposed Cohort (NB exposure = intervention)
Item is assessing the representativeness of exposed individuals in the community, not the representativeness of the study sample from
some general population. For example, subjects derived from groups likely to contain exposed people are likely to be representative of
exposed individuals, while they are not representative of all people the community.
Allocation of stars as per rating sheet
2) Selection of the Non-Exposed Cohort
Allocation of stars as per rating sheet
3) Ascertainment of Exposure
Allocation of stars as per rating sheet
4) Demonstration That Outcome of Interest Was Not Present at Start of Study
In the case of mortality studies, outcome of interest is still the presence of a disease/ incident, rather than death. That is to say that a
statement of no history of disease or incident earns a star.
A maximum of 4 stars can be allotted in Selection.
COMPARABILITY
1) Comparability of Cohorts on the Basis of the Design or Analysis
Either exposed and non-exposed individuals must be matched in the design and/or confounders must be adjusted for in the analysis.
Statements of no differences between groups or that differences were not statistically significant are not sufficient for establishing
comparability. Note: If the relative risk for the exposure of interest is adjusted for the confounders listed, then the groups will be
considered to be comparable on each variable used in the adjustment.
A maximum of 2 stars can be allotted in this category.
OUTCOME
2) Assessment of Outcome
For some outcomes, reference to the medical record is sufficient to satisfy the requirement for confirmation. This may not be adequate
for other outcomes where reference to specific tests or measures would be required.
a) Independent or blind assessment stated in the paper, or confirmation of the outcome by reference to secure records (health records,
etc.)
b) Record linkage (e.g. identified through ICD codes on database records)
c) Self-report (i.e. no reference to original health records or documented source to confirm the outcome)
d) No description.
3) Was Follow-Up Long Enough for Outcomes to Occur
An acceptable length of time should be decided before quality assessment begins.
4) Adequacy of Follow Up of Cohorts
This item assesses the follow-up of the exposed and non-exposed cohorts to ensure that losses are not related to either the exposure or
the outcome.
A maximum of 3 stars can be allotted in this category.
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Appendix 4. Studies in progress
There are a number of ongoing trials of Treatment as Prevention in Africa that are worth noting:
“MP3: An HIV Prevention Package for Mochudi” is a large, ongoing NIH-funded trial in Botswana of 14,000 men and women that
will assess transmission on a community level as a result of a number of interventions (including education, behavior modification,
circumcision, and use of ART). Results are expected in 2013.
“HIV VCT and Linkage to Care in Uganda” is a large NIH-funded trial in Uganda of 3,314 men and women that aims to estimate
the impact of enhanced counseling and testing services on reducing HIV risk behavior. Furthermore, the trial will test whether an
enhanced linkage to HIV-specific medical care is more effective than usual referral in receipt of ART and reducing mortality. Results
are expected in 2013.
“TasP Study”--a French National Agency for AIDS Research (ANRS) study (12249) is a trial in South Africa that aims to test 5000
people for HIV and offer approximately 750 HIV-positive individuals ARV treatment. In turn, the study will assess widespread HIV
testing and prevention services in an immediate treatment arm versus a delayed treatment arm (according to CD4 level). The trial is
scheduled to start in 2012.
“PopART: Population effects of antiretroviral therapy to reduceHIV transmission”-(HPTN071) is a large trial proposed to be conducted
across 24 communities in South Africa and Zambia. The intervention will be deployed to approximately 600,000 adults with 60,000
adults included in the evaluation cohort. The main objective is to measure the impact of immediate treatment, regardless of CD4, on
HIV incidence when compared to treatment offerred according to the national guidelines. The protocol is currently in sponsor review
process and results are expected in 2015.
WH A T ’ S N E W
Last assessed as up-to-date: 26 February 2013.
Date Event Description
26 February 2013 New citation required but conclusions have not
changed
Update. Conclusions not changed.
26 February 2013 New search has been performed New searches and screening. Added two new observa-
tional studies
H I S T O R Y
Review first published: Issue 5, 2011
Date Event Description
8 October 2011 Amended Correction in regard to DSMB
8 August 2011 New search has been performed Toxicity and adverse events data added
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(Continued)
19 May 2011 New search has been performed Randomised controlled trial added
19 May 2011 New citation required and conclusions have changed Evidence of effect rated as high
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I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Sexual Partners; Anti-HIV Agents [∗therapeutic use]; CD4 Lymphocyte Count; Cohort Studies; HIV Infections [∗prevention &
control; ∗transmission]; HIV Seronegativity; HIV Seropositivity [drug therapy; transmission]; HIV Serosorting
MeSH check words
Female; Humans; Male
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